Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria

Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines are among the variety of implemented cost-containment measures aimed at reducing and controlling the rising cost for pharmaceuticals. The aim of our study was to analyze the influence of a recently introduced measure in Bulgaria—budget capping in terms of overall budget expenditure. A secondary goal was to analyze current and extrapolate future trends in the healthcare and pharmaceutical budget based on data from 2016 to 2021. The study is a retrospective, observational and prognostic, macroeconomic analysis of the National Health Insurance Fund's (NHIF) budget before (2016–2018) and after (2019–2021) the introduction of the new budget cap model. Subgroups analysis for each of the three new budget groups of medicines (group A: medicines for outpatient treatment, prescribed after approval by a committee of 3 specialists; group B: all other medicines out of group A; and group C: oncology and life-saving medicines out of group A) was also performed, and the data were extrapolated for the next 3 years. The Kruskal–Wallis test was applied to establish statistically significant differences between the groups. During 2016–2021, healthcare services and pharmaceutical spending increased permanently, observing a growth of 82 and 80%, respectively. The overall healthcare budget increased from European €1.8 billion to 3.3 billion. The subgroup analysis showed a similar trend for all three groups, with similar growth between them. The highest spending was observed in group C, which outpaced the others mainly due to the particular antineoplastic (chemotherapy) medicines included in it. The rising overall healthcare cost in Bulgaria (from European €1.8 billion to 3.3 billion) reveals that implementation of a mechanism for budget predictability and sustainability is needed. The introduced budget cap is a relatively effective measure, but the high level of overspending and pay-back amount (from European €34 billion to 59 billion during 2019–2021) reveals that the market environmental risk factors are not well foreseen and practically implemented.

[1]  G. Petrova,et al.  Analysis of the Household and Health Care System Expenditures in Bulgaria , 2021, Frontiers in Public Health.

[2]  R. Dubois,et al.  The Dollar or Disease Burden: Caps on Healthcare Spending May Save Money, but at What "Cost" to Patients? , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  T. Vetter,et al.  Nonparametric Statistical Methods in Medical Research , 2020, Anesthesia and analgesia.

[4]  M. Jakovljevic,et al.  Gross Domestic Product and Health Expenditure Growth in Balkan and East European Countries—Three-Decade Horizon , 2020, Frontiers in Public Health.

[5]  A. Feigl,et al.  Assessing the future medical cost burden for the European health systems under alternative exposure-to-risks scenarios , 2020, PloS one.

[6]  Carsten Colombier,et al.  Budgetary targets as cost-containment measure in the Swiss healthcare system? Lessons from abroad , 2020, Health Policy.

[7]  Elias Mossialos,et al.  The ‘Netflix plus model’: can subscription financing improve access to medicines in low- and middle-income countries? , 2020, Health Economics, Policy and Law.

[8]  M. Naylor,et al.  Adapting Andersen’s expanded behavioral model of health services use to include older adults receiving long-term services and supports , 2020, BMC Geriatrics.

[9]  P. Kanavos,et al.  Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. , 2019, Health policy.

[10]  F. Suleman,et al.  Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis , 2019, BMC Health Services Research.

[11]  M. Niewada,et al.  Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries. , 2018, Health policy.

[12]  Panos Kanavos,et al.  The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications , 2017, PharmacoEconomics (Auckland).

[13]  P. Kefalas,et al.  Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test , 2017, Journal of market access & health policy.

[14]  L. Garattini,et al.  Reimbursable drug classes and ceilings in Italy: why not only one? , 2016, The European Journal of Health Economics.

[15]  J. Puig-Junoy,et al.  Predictors of primary health care pharmaceutical expenditure by districts in Uganda and implications for budget setting and allocation , 2015, BMC Health Services Research.

[16]  Z. Kaló,et al.  Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland , 2014 .

[17]  S. Ólafsson.  Review of Issues , 2014 .

[18]  C. Walton.  Entering a new era , 2013 .

[19]  Ana Aizcorbe,et al.  Price Indexes for Drugs: A Review of the Issues , 2013 .

[20]  L. Lorenzoni,et al.  Informing policy makers about future health spending: a comparative analysis of forecasting methods in OECD countries. , 2012, Health policy.

[21]  A. Oxman,et al.  Pharmaceutical policies: effects of cap and co-payment on rational drug use. , 2008, The Cochrane database of systematic reviews.

[22]  W. Diewert,et al.  Harmonized Indexes of Consumer Prices: Their Conceptual Foundations , 2002, SSRN Electronic Journal.

[23]  P. Kanavos,et al.  Controlling expenditure within the Spanish pharmaceutical market: Macro- and micro-level policy approaches , 2017 .

[24]  Eugenio Lilli.  Findings and Implications , 2016 .

[25]  L. Garattini,et al.  Italian risk-sharing agreements on drugs: are they worthwhile? , 2014, The European Journal of Health Economics.

[26]  M. Almiñana,et al.  Análisis de series temporales del coste de los grupos terapéuticos más utilizados en un servicio de medicina intensiva , 2007 .

[27]  S. Asia.  WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR , 2003 .